Loading data for OTLK — first visit, this takes a few seconds.

Outlook Therapeutics, Inc. (OTLK)

NasdaqCM: OTLK · Real-Time Price · USD

0.67

+0.02 (3.08%)

At close: Sep 09, 2026, 5:57 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	0.48
Market Cap	155M
Revenue (ttm)	-1.16M
Net Income (ttm)	-61.1M
	0.75
	-0.7
	n/a
	-4.57
P/B (ttm)	-11.42
P/S (ttm)	-133.36
Earnings Date	Dec 18, 2026

Ask	0.68
Volume	6,354,446
Avg. Volume (20D)	17,749,816
Open	0.66
Previous Close	0.65
Day's Range	0.65 - 0.70
52-Week Range	0.16 - 2.54
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About OTLK

Outlook Therapeutics, Inc., operates as a clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic bevacizumab product formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has col...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Jun 14, 2016

Employees 17

Stock Exchange NasdaqCM

Ticker Symbol OTLK

Website https://outlooktherapeutics.com

Full Company Profile

Financial Performance

In 2025, Outlook Therapeutics's revenue was 1.41M, an increase of undefined% compared to the previous year's 0. Earnings were -62.42M, a decrease of -17.17%.

Financial Statements

Earnings Surprise

Outlook Therapeutics has released their quarterly earnings on Aug 14, 2026:

Revenue of $127.44K misses estimates by $0, with Infinity% YoY growth.
EPS of -0.09 misses estimates by -0.02, with 79.55% YoY growth.

Next Earnings Release

Outlook Therapeutics, Inc. is scheduled to release its earnings on Dec 18, 2026, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

3 weeks ago · Zacks

OTLK Q3 Earnings Call Maps LYTENAVA U.S. Launch and Sales Ramp

Outlook Therapeutics targets a year-end 2026 U.S. LYTENAVA launch, with $50M-$75M in first-year net revenues and a ramp tied to reimbursement.

3 weeks ago · Simply Wall St.

Outlook Therapeutics (OTLK) Stock May Be No Bargain With Approval But Weak Balance Sheet

Outlook Therapeutics stock has been through a very rough stretch over the past few years, and the current checks suggest it still does not screen as a clear bargain despite the recent approval and upc...

3 weeks ago · MarketBeat

Oncobiologics Q3 Earnings Call Highlights

Oncobiologics (NASDAQ:OTLK) said it is preparing for the U.S. commercial launch of LYTENAVA after the Food and Drug Administration approved the product as the only FDA-approved ophthalmic formulation ...

3 weeks ago · Moby

Outlook Therapeutics, Inc. Q3 2026 Earnings Call Summary

Moby summary of Outlook Therapeutics, Inc.'s Q3 2026 earnings call

3 weeks ago · Zacks

Outlook Therapeutics, Inc. (OTLK) Reports Q3 Loss, Lags Revenue Estimates

Outlook Therapeutics, Inc. (OTLK) delivered earnings and revenue surprises of 0.00% and -99.25%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the sto...

Page 1 of 2

Outlook Therapeutics, Inc. (OTLK)